BIOVECTRA
BIOVECTRA is a North American contract development and manufacturing organization (CDMO) specializing in clinical-to-commercial scale production capabilities for biologics, synthetic small molecules, pDNA and mRNA, highly potent active pharmaceutical ingredients (APIs) and bioreagents. They thrive on the vexing challenges few CDMOs would have the expertise or desire to address. Bold vision, along with the passion and commitment to make that vision a reality, is at the heart of their organization.
Latest Content
Product News
BIOVECTRA Is Honored With 2025 CDMO Leadership Award for Biologics
BIOVECTRA, part of Agilent Technologies, has been awarded the 2025 Outsourced Pharma CDMO Leadership Award in biologics for its exceptional quality, reliability and technical capability.
Online Event
Innovations in Biopharma 2025
New for 2025, this event will provide insights from both big pharma and emerging biotech firms. Attendees will gain a comprehensive understanding of how rapid technological advancements are reshaping therapeutic development and delivery.
Article
A Bright Future for RNA Therapeutics
RNA therapeutics promise rapid, personalized and flexible treatments against multiple diseases. In this article, we will explore whether RNA therapeutics can realize their full potential.
Webinar
Manufacturing High Quality and Purity Antibody–Drug Conjugates
On-Demand
This webinar highlights key strategies for advancing ADC manufacturing, featuring expert insights and best practices for overcoming common challenges.
Webinar
Optimizing mRNA Manufacturing: Overcoming Supply Chain Challenges With CDMO Solutions
On-Demand
In this webinar, our expert speaker will explore the benefits of partnering with an integrated contract development and manufacturing organization (CDMO) that can guide nucleic acid products from development through to commercial manufacturing.
Listicle
Cell Therapy: Clinical Applications, Manufacturing and Regulation
Download this listicle to learn more about the applications of cell therapy, the regulatory landscape of cell therapy, and manufacturing and scalability challenges.
Product News
Biovectra Signs Service Agreement With Acuitas Therapeutics for Unique Lipid Nanoparticle (Lnp) Delivery System Used in Manufacturing mRNA-Based Therapies
Partnership between two Canadian life sciences leaders offers a commercial GMP manufacturing solution for Acuitas’ licensed partners developing promising next generation therapies.
Whitepaper
Discover Single-Use Fermenters for Biopharmaceutical Production
Single-use fermenters (SUFs) use disposable sterile plastic bags that don’t require the traditional high-intensity preparation of SS bioreactors, which are expensive and time-consuming processes.
Advertisement
